GH News & Events

Guardant Health announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU, developed and commercialized by Daiichi Sankyo in Japan, for the treatment of patients with HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by Japan's Ministry of Health, Labour and Welfare, MHLW, was supported by data from the HERALD, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 clinical trials and supplemental real-world evidence, RWE, generated using the real-world data platform from InfinityAI, Guardant Health's artificial intelligence platform.

Verana Health has announced a new partnership with Guardant Health that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care. Guardant's extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while Verana Health's highly curated data tracks a patient's complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens Verana Health's data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data set with considerable patient overlap for enhanced clinical insights.